Abstract
The study of biomarkers has great promise for advancing knowledge in clinical practice and research in mental health. Biomarkers have the potential to improve our ability to diagnose individuals with a psy chiatric disorder, to screen populations at risk of devel oping disorders, to provide prognostic information to those who manifest prodromal signs or to those who already have a disorder, and to help individuals make decisions about the most appropriate treatments (treat ment response). However, there are many methodologi cal and statistical issues that must be kept in mind as biomarkers are validated in research studies and before they can be considered useful for clinical practice.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Szatmari P, Maziade M, Zwaigenbaum L, et al. Informative phenotypes for genetic studies of psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet 2007;144:581–588
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Ed. Text Revision. Arlington, VA: American Psychiatric Press; 2000
World Health Organization. International statistical classifi ca tion of diseases and related health problems: tenth revision. 2nd Ed. Geneva, Switzerland: World Health Organization; 2004
Helzer JE, Kraemer HC, Krueger RF. The feasibility and need for dimensional psychiatric diagnosis. Psychol Med 2006;36:1671–1680
Maier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci 2008;258(1, Suppl): 12–20
Land JM. Evidence-based medicine: evaluation of biomarkers. In: Trull AK, Demers LM, Holt DW, Johnston A, Price CP, Tredger MJ (eds.) Biomarkers of disease: an evidence-based approach. Cambridge: Cambridge University Press; 2002, pp. 390–397
Hulka BS, Margolin BH. Methodological issues in epide-miologic studies using biologic markers. Am J Epidemiol 1992;135:200–209
Simon R. Validation of pharmacogenomic biomarker classi-fi ers for treatment selection. Cancer Biomark 2006;2:89–96
Moore RA. Evidence-based medicine: evaluation of bio-markers. In: Trull AK, Demers LM, Holt DW, Johnston A, Price CP, Tredger MJ (eds.) Biomarkers of disease: an evi dence-based approach. Cambridge: Cambridge University Press; 2002, pp. 3–15
Lijmer JG, Willem Mol B, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061–1066
Rutjes AWS, Reitsma JB, DiNisio M, et al. Evidence of bias and variation in diagnostic accuracy studies. CMAJ [serial online] 2006;174:DOI:10.1503/cmaj.050090
Baker SG, Kramer BS, McIntosh M, et al. Evaluating mark ers for the early detection of cancer: overview of study designs and methods. Clin Trials 2006;3:43–56
Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106–1110
Rasumussen-Torvik LJ, McAlpine DD. Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils. Depress Anxiety 2007;24:350–357
Barnett JH, Heron J, Ring SM, et al. Gender-specific effects of the catechol-O-methyltransferase Val108/158Met poly morphism on cognitive function in children. Am J Psychiatry 2007;164:142–149
Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. Designing Clinical Research. 3rd Ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007
Kelsey JL, Whittemore AS, Evans AS, et al. Methods in observational epidemiology. 2nd Ed. New York: Oxford University Press; 1996, pp. 311–340
McGuffin P, Cohen S, Knight J. Homing in on depression genes. Am J Psychiatry 2007;164:195–197
Pai M, Flores LL, Pai N, et al. Diagnostic accuracy of nucleic acid amplifi cation tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2003;3:633–643
Boyle MH. Sampling in epidemiologic studies. In: Verhulst FC, Koot HM (eds.) The epidemiology of child and adoles cent psychopathology. Oxford: Oxford University Press; 1995, pp. 66–84
Keshavan MS, Stanley JA, Pettegrew JW. Magnetic reso nance spectroscopy in schizophrenia: methodological issues and fi ndings — part II. Biol Psychiatry 2000;48:369–380
Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole-genome association studies. Nature 2004;429:446–452
Chow S-C, Shao J, Wang H. Sample size calculations in clini cal research. Basel, Switzerland; Marcel Dekker Inc; 2003
Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. JAMA 1995;274: 645–651
Nierenberg AA, Feinstein AR. How to evaluate a diagnostic marker test. JAMA 1988;259:1699–1702
Litvan I. Methodological and research issues in the evalua tion of biological diagnostic markers for Alzheimer's dis ease. Neurobiol Aging 1998;19:121–123
Bolanna AA, Arranz MJ, Mancama D, et al. Pharmaco-genomics — can genetics help in the care of psychiatric patients? Int Rev Psychiatry 2004;16:311–319
Jones DS, Perlis RH. Pharmacogenetics, race, and psychia try: prospects and challenges. Harvard Rev Psychiatry 2006;14:92–106
Bondy S, Spellmann I. Pharmacogenetics of antipsychotics: useful for the clinician? Curr Opin Psychiatry 2007;20: 126–130
Gordon E, Liddell BJ, Brown KJ, et al. Integrating objective gene-brain-behavior markers of psychiatric disorders. J Integr Neurosci 2007 Mar;6(1):1–34.
Kelsey JL, Whittemore AS, Evans AS, et al. Methods in observational epidemiology. 2nd Ed. New York: Oxford University Press; 1996:355
Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003;49:7–18
Streiner DL. Diagnosing tests: using and misusing diagnostic and screening tests. J Pers Assess 2003;81:209–219
Almasy L. Quantitative risk factors as indices of alcoholism susceptibility. Ann Med 2003;35:337–343
Alarcon M, Cantor R, Lieu J, et al. Evidence for a language quantitative trait locus on chromosome 7q in multiple autism families. Am J Hum Genet 2002;70:60–71
Kardon RH. Drop the Alzheimer's drop test. Neurology 1998;50:588–591
Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003;24:521–536
Michels Blanck H, Bowman BA, Cooper GR, et al. Laboratory issues: use of nutritional biomarkers. J Nutr 2003;133:888S–894S
Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia. An overview of the evidence and its therapeutic implications. CNS Drugs 2001;15:287–310
Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407–418
Altman DG, Royston P. The cost of dichotomizing continu ous variables. BMJ 2006;332:1080
Sackett D, Straus S. On some clinically useful measures of the accuracy of diagnostic tests. ACP J Club 1998; 129:A17–A19
Kathmann N, Hochrein A, Uwer R, et al. Defi cits in gain of smooth pursuit eye movements in schizophrenia and affec tive disorder patients and their unaffected relatives. Am J Psychiatry 2003;160:696–702
Bender S, Weisbrod M, Resch F. Which perspectives can endo-phenotypes and biological markers offer in the early recogni tion of schizophrenia? J Neural Transm 2007;114:1199–1215
Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636–645
Mossner R, Mikova O, Koutsilieri E, et al. Consensus paper on the WFSBP task force on biological markers: biological mark ers of depression. World J Biol Psychiatry 2007;8:141–174
Shaw LM, Korecka M, Clark CM, et al. Biomarkers of neu-rodegeneration for diagnosis and monitoring of therapeu tics. Nat Rev Drug Discov 2007;6:295–303
Bailey P. Biological markers in Alzheimer's disease. Can J Neurol Sci 2007;34(1, Suppl):S72–S76
Vitzhum F, Behrens F, Anderson NL, et al. Proteomics: from basic research to diagnostic application. A review of require ments and needs. J Proteome Res 2005;4:1086–1097
Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? JAMA 1994;271:389–391
Fleiss JL. Statistical methods for rates and proportions. 2nd Ed. New York: Wiley-Interscience; 1981
Burke MJ, Preskorn SH. Therapetuci drug monitoring of antidepressants. Cost implications and relevance to clinical practice. Clin Pharmacokinet 1999;37:147–165
Vuille F, Amey M, Baumann P. Use of serum level monitor ing of antidepressants in clinical practice. Pharmacopsychiatry 1991;24:190–195
Mann K, Hiemke C, Lotz J, Schmidt LG, Lackner KJ, Bates DW. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpa tients with affective disorders. J Clin Psychopharmacol 2006;26:671–673
Price GW, Michie PT, Johnston J, et al. A multivariate elec-trophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian Family study of schizophrenia. Biol Psychiatry 2006;60:1–10
Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173–1182
Caspi A, Moffi tt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyl-transferase gene: longitudinal evidence of a gene X environ ment interaction. Biol Psychiatry 2005;57:1117–1127
Bostwick DG, Adolfsson J, Burke HB, et al. Epidemiology and statistical methods in prediction of patient outcome. Scand J Urol Nephrol 2005;39(3);94–110.
McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer 2005;93:387–391
Moher D, Schulz KF, Altman D for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group random ized trials. JAMA 2001;285:1987–1991
von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806–808
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Van Lieshout, R.J., Szatmari, P. (2009). Methodological and Statistical Issues in the Use of Biomarkers in Clinical and Research Studies. In: Ritsner, M.S. (eds) The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-9464-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4020-9464-4_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-9463-7
Online ISBN: 978-1-4020-9464-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)